Staff Members - Benha University
Significance of BRAF and Nrf2 in evaluation of serous ovarian tumors
Egyptian Journal of Pathology • 2020
Publication Information
Authors
Amira E. Solimana, Ghada A. Abd El-Fattaha, Taghreed A. Abd Elaziza,Magda H. Nasreldinb, Ahmed M. Khalilc, Hala A. Aginaa
Keywords
BRAF, immunohistochemistry, nuclear factor erythroid 2-related factor 2, serous ovarian
tumors
Journal
Egyptian Journal of Pathology
Publisher
Wolters Kluwer - Medknow
Volume
40
Issue
Not Available
Pages
28-36
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Background
Ovarian carcinoma is the second leading cause of cancer-related deaths among
women. Many treatment strategies have been developed; however, the prognosis
is still poor. This study aims to evaluate the immunohistochemical expression of the
serine/threonine-protein kinase B-raf (BRAF) and nuclear factor erythroid 2-related
factor 2 (Nrf2) in serous ovarian tumors and to correlate their expression with
clinicopathological features of the cases.
Materials and methods
This uncontrolled retrospective study was performed on 50 cases: benign (n=10),
borderline (n=12), and malignant serous ovarian neoplasm (n=28). The malignant
serous tumors included nine low-grade cases and 19 high-grade cases. The
immunohistochemical expression of Nrf2 and BRAF was correlated with
clinicopathological features of prognostic importance.
Results
The mean of BRAF expression is increased in borderline but it is almost equal for
low-grade and high-grade carcinoma cases, which was statistically significant
(P
Ovarian carcinoma is the second leading cause of cancer-related deaths among
women. Many treatment strategies have been developed; however, the prognosis
is still poor. This study aims to evaluate the immunohistochemical expression of the
serine/threonine-protein kinase B-raf (BRAF) and nuclear factor erythroid 2-related
factor 2 (Nrf2) in serous ovarian tumors and to correlate their expression with
clinicopathological features of the cases.
Materials and methods
This uncontrolled retrospective study was performed on 50 cases: benign (n=10),
borderline (n=12), and malignant serous ovarian neoplasm (n=28). The malignant
serous tumors included nine low-grade cases and 19 high-grade cases. The
immunohistochemical expression of Nrf2 and BRAF was correlated with
clinicopathological features of prognostic importance.
Results
The mean of BRAF expression is increased in borderline but it is almost equal for
low-grade and high-grade carcinoma cases, which was statistically significant
(P